Friday, January 10, 2020 9:42:03 AM
Still think Waggs will/has not announce(d) submission...
I personally think its in
That's possible. With the last PR pump of 4 days ago being a charade.
I don't expect Kenny to ever announce the mythical IND submission, whether it goes in or not. Neither is it expected that Kenny will commit to doing so. Along with giving the final specifics of the mythical CT protocol to SHs.
All of this means, SHs get to guess. Speculate whether it has gone in or not. Speculate whether or not the FDA accepted it. Without knowing if or when the 30 day FDA clock has started, only speculation will be left.
Also, since the biotech industry doesn't announce when they submit INDs, but rather only when CTs start, PMCB has justification for not filing an 8K upon an IND filing. The industry doesn't consider the first IND filing as a material event. I've seen some give CC updates for late stage Phase 2, or before entering Phase 3. Thus, neither would its rejection be considered a material event for PMCB. Kenny could sit on a rejection for weeks. Gives him more time to issue PR pumps for a recovery from such an event. Yet another reason(s) he is extremely unlikely to announce any submission.
I personally think its in
That's possible. With the last PR pump of 4 days ago being a charade.
I don't expect Kenny to ever announce the mythical IND submission, whether it goes in or not. Neither is it expected that Kenny will commit to doing so. Along with giving the final specifics of the mythical CT protocol to SHs.
All of this means, SHs get to guess. Speculate whether it has gone in or not. Speculate whether or not the FDA accepted it. Without knowing if or when the 30 day FDA clock has started, only speculation will be left.
Also, since the biotech industry doesn't announce when they submit INDs, but rather only when CTs start, PMCB has justification for not filing an 8K upon an IND filing. The industry doesn't consider the first IND filing as a material event. I've seen some give CC updates for late stage Phase 2, or before entering Phase 3. Thus, neither would its rejection be considered a material event for PMCB. Kenny could sit on a rejection for weeks. Gives him more time to issue PR pumps for a recovery from such an event. Yet another reason(s) he is extremely unlikely to announce any submission.
The Jewel of the Mind is Colored with the Hue of what it Imagines
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
